Evidence mapPaperPMID 39770075Full record

ReviewMolecules (Basel, Switzerland)2024

The Anti-AGEing and RAGEing Potential of Isothiocyanates.

Bradley A Krisanits, Bhoomika Kaur, Jed W Fahey, David P Turner

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Watercress (Life (Basel, Switzerland) · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bradley A KrisanitsDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA.
Bhoomika KaurDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA.
Jed W FaheyDepartments of Medicine, Pharmacology & Molecular Sciences, Psychiatry & Behavioral Sciences, and iMIND Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-2129-1834
David P TurnerDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA.ORCID 0000-0003-3667-8844

Funding

Training Program in Cancer Prevention and ControlT32CA093423 · VIRGINIA COMMONWEALTH UNIVERSITY · 2025 to 2025
$464k
NCI NIH HHS T32 CA093423NIH-NCI R01CA259415-02; R01CA245143; P30CA016059
6 · The paper itself

Abstract

Isothiocyanates (ITCs), found in edible plants such as cruciferous vegetables, are a group of reactive organo-sulfur phytochemicals produced by the hydrolysis of precursors known as glucosinolates. ITCs have been studied extensively both in vivo and in vitro to define their therapeutic potential for the treatment of chronic health conditions. Therapeutically, they have shown an intrinsic ability to inhibit oxidative and inflammatory phenotypes to support enhanced health. This review summarizes the current evidence supporting the observation that the antioxidant and anti-inflammatory activities of ITCs temper the pathogenic effects of a group of reactive metabolites called advanced glycation end products (AGEs). AGE exposure has significantly increased across the lifespan due to health risk factors that include dietary intake, a sedentary lifestyle, and comorbid conditions. By contributing to a chronic cycle of inflammatory stress through the aberrant activation of the transmembrane receptor for AGE (RAGE), increased AGE bioavailability is associated with chronic disease onset, progression, and severity. This review debates the potential molecular mechanisms by which ITCs may inhibit AGE bioavailability to reduce RAGE-mediated pro-oxidant and pro-inflammatory phenotypes. Bringing to light the molecular impact that ITCs may have on AGE biogenesis may stimulate novel intervention strategies for reversing or preventing the impact of lifestyle factors on chronic disease risk.

Indexed as

AgingGlycation End Products, AdvancedIsothiocyanatesReceptor for Advanced Glycation End ProductsAnimalsAnti-Inflammatory AgentsAntioxidantsHumansOxidative StressAnti-Inflammatory AgentsAntioxidantsGlycation End Products, AdvancedIsothiocyanatesReceptor for Advanced Glycation End Productsadvanced glycation end productsallyl isothiocyanatebenzyl isothiocyanatechronic diseaseinflammationisothiocyanatelifestyleoxidative stressphenethyl isothiocyanatereceptor for advanced glycation end productssulforaphane

Identifiers

PMID39770075
PMCPMC11677037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.